Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
IRSB registration revoked:
https://www.sec.gov/litigation/admin/2019/34-86717.pdf
08/21/2019 08:40:56 12(j)Registration Revoked by SEC 08/21/2019 08:41:00
IRSB
Iris Biotechnologies, Inc. Common Stock
IRSB SEC Suspension for delinquent Financials:
https://www.sec.gov/litigation/suspensions/2019/34-86527.pdf
Order:
https://www.sec.gov/litigation/suspensions/2019/34-86527-o.pdf
Admin. Proceeding:
https://www.sec.gov/litigation/admin/2019/34-86526.pdf
IRSB... .11...Williams bottomed out here as the 50/200 cross just executed on this low floater...A slew of Form 4s showing the ceo taking shares as compensation...
Market Value1 $2,350,481 a/o Aug 16, 2017
Authorized Shares 100,000,000 a/o March 18, 2016
Outstanding Shares 21,368,011 a/o Nov 14, 2016
Float 5,956,081 a/o Apr 11, 2016
wonder if the bid uptick and disappearance of the 100K+ seller(s) will hold...
SANTA CLARA, Calif. --(BUSINESS WIRE)-- Iris Biotechnologies announces that the Japanese Patent Office has issued a notice of allowance of its Artificial Intelligence System for Genetic Analysis to be granted as a patent. This follows the issuance of a family of patents in the US, EU, Canada , Hong Kong , Australia, and New Zealand .
A critical mass of scientific knowledge, instrumentation and affordable computing power is at hand, yet a critical piece has been missing which Iris is now able to provide: smart integration of genomic, proteomic, lifestyle, family history and environmental information. Iris is poised to play a leading role in answering the unmet needs of a multi-billion-dollar market.
"Compared to when Iris Biotechnologies common stock (IRSB) was trading at $4.50 per share, the Company now has more patents worldwide and is planning to launch the first Iris Wellness Labs this summer," said Iris CEO Simon Chin . To read more about Iris Wellness services, please visit ir.irisbiotech.com under Quick Links.
About Iris Biotechnologies Inc.
Iris Biotechnologies Inc. (OTC MKTS: IRSB), unlike other life sciences companies, focuses on providing accurate, affordable precision healthcare through comprehensive analysis of the whole person inside and out. Iris offers the best approach to the treatment of cancer and other diseases through incorporating DNA, RNA and protein analysis with a patient's medical records, family medical history, life style and environmental exposures. Iris enables personalized, cost-effective healthcare and is the future of precision medicine.
Forward-looking Statements
Statements in this presentation about the Company's expectations, applications of its technology, markets, launch of tests and other statements that are not historical facts are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are based on management's current beliefs, assumptions, estimates and projections. Actual results may differ materially from those projected in the forward-looking statements for various reasons, including risks associated with product and test development, test transfer to contracting labs, government regulation, market acceptance, limited commercial experience, dependence on key personnel, obtaining financing and other factors discussed in the Company's periodic reports filed with the Securities and Exchange Commission .
View source version on businesswire.com: http://www.businesswire.com/news/home/20160613005173/en/
CONTACT: Iris Biotechnologies Inc.
Simon Chin , 408-806-7149
President and CEO
simonchin@irisbiotech.com
Source: Iris Biotechnologies Inc.
SANTA CLARA, CA -- (Marketwired) -- 05/23/16 -- Iris BioTechnologies Inc. (OTC PINK: IRSB) announces its BioWindows™ 3-Risk Scores System for Multi-Omic Analysis, which will be offered through its subsidiary, Iris Wellness Labs . The System performs intricate correlations, while presenting results in a user-friendly visual format, allowing physicians and patients to understand and act on complex molecular information.
Simon Chin , Iris BioTechnologies President and CEO, stated, "The 3-Risk system can have an immediate impact on saving and improving the quality of life for many people. Through decades of dedicated hard work, Iris makes things easier for its customers."
With Iris's 3-Risk™ Analysis System, a patient can see his or her risk of disease, mortality and recurrence for a variety of diseases using a combination of genomics, proteomics, and other analytics. This offers an opportunity for physicians and patients to discuss medical treatment, disease-free survival and overall survival in a more informed context.
Each person's unique DNA is important, but life involves a continuous conversation between a person's DNA and its molecular world. To turn the vast pool of molecular activity into clinically useful information, one must look at the whole picture: DNA sequence, gene expression, protein expression, lifestyle and environment.
In analyzing DNA itself, it is important to understand single molecule substitutions, insertions and deletions, copy number variations, and chromosome translocations. Getting one's DNA sequenced is just the beginning. What is more important is to understand the significance of the changes in one's DNA.
Using next-generation sequencing (NGS) technology, one's DNA variances can be examined for personal medical risk association. Variances may be sorted into different categories such as known disease-associated mutation, predicted disease-associated mutation, variant of unknown significance, and others. Knowing the right categorization and seeing risk association easily has the potential to inform and save lives.
NGS can also be used to determine gene expression. In the Iris 3-Risk System, gene expression and protein expression information, obtained by using technologies that exist today, are incorporated into the analysis process.
Iris's approach involves complex Big Data analytics, genomics, and proteomics, in relation to wellness and disease progression. The company's technology is based upon the understanding of medicine, biology, chemistry, nanotechnology, semiconductor manufacturing, and microfluidics. Iris has created intellectual properties in methods, devices, and systems.
Cancer Treatment : Getting the Right Actionable Information
President Richard Nixon declared the "War on Cancer" more than 40 years ago. While progress has been made in some areas, cancer remains the emperor of all maladies. With the Iris 3-Risk Scores System, Iris can overcome the problem of getting too little information or being seized by information overload. Getting the right information at the right time can be a matter of life and death.
A picture is worth a thousand words. To see a sample image of part of the Iris BioWindows 3-Risks System, please look at the "Investor Presentation" posted on the Iris website at ir.irisbiotech.com under Quick Links. Cancer, human genomes, and the Iris 3-Risk System are complex and cannot be adequately described in a press release. To better understand how they are related, please read, "Understanding the Genome" under Quick Links.
In the Iris BioWindows 3-Risks System, the smart phone will be the primary medical interface between Iris, consumers, patients, and the medical community. We also enable computer access to secure, cloud-based, vital wellness and medical information.
About Iris BioTechnologies Inc.
Iris BioTechnologies Inc. (OTC PINK: IRSB) is a life sciences company focused on providing accurate, affordable precision healthcare. Unlike other companies, Iris looks at the whole picture and is the future of medicine. Iris offers the best approach to the treatment of cancer and other diseases through actionable integration of molecular profiling in the clinical decision-making process. In the treatment of cancer, Iris can achieve precision analysis of chemotherapy effectiveness as well as risk of recurrence. Iris accomplishes this by incorporating DNA, RNA and protein analysis with a patient's medical records, family medical history, life style and environmental exposures. Iris enables personal precision healthcare by matching patient to targeted treatments, and in some cases, including therapies in clinical trials.
The Iris Nano-Biochip™ product pipeline includes: CancerChip™, Integrated Blood Test, NeuroChip™ (Alzheimer's and Parkinson diseases), MetabolicChip™ (Diabetes), CardioChip™, and Chips for veterinary, agricultural, environmental, and other applications. The Iris BioWindows™ artificial intelligence system provides big data and analysis for clinical applications, drug development, and stem cell research.
Forward-looking Statements
Statements in this presentation about the Company's expectations, applications of its technology, markets, launch of tests and other statements that are not historical facts are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are based on management's current beliefs, assumptions, estimates and projections. Actual results may differ materially from those projected in the forward-looking statements for various reasons, including risks associated with product and test development, test transfer to contracting labs, government regulation, market acceptance, limited commercial experience, dependence on key personnel, obtaining financing and other factors discussed in the Company's periodic reports filed with the Securities and Exchange Commission .
For more information on Iris BioTechnologies , please visit Iris on Facebook (https://www.facebook.com/irisbiotech), Twitter (https://twitter.com/irisbiotech), and the Iris corporate website (www.irisbiotech.com).
Iris BioTechnologies Inc.Simon Chin408-806-7149President and CEOsimonchin@irisbiotech.com
Source: Iris BioTechnologies Inc.
per the 10-k, "On March 17, 2016, in preparation for our multiple product launches, our board of directors unanimously approved the increase of our authorized shares..."
don't blame anyone from reacting to this, and if i wasn't holding freebies from the bottom bounce, i might do the same.
We need a little positive news to get this moving again!
after another seemingly random bout of volatility, the bid appears to be slowly ticking up again... back to .23x.40
Hello is there anyone out there? Apparently the company isn't doing much of anything, at least worthy enough to report.
ask uptick, now .30x.53. NITE must have dozed off again (up @1.00 now)
agreed on all fronts
Sleepers have been my biggest gainers. I'm ridding freebies so I can wait but as you know it takes very little vol to get this moving. Get some news/vol and it's on.
Maybe so but that is without any news??
Zzzzz 11% on 1000
With a little volume and news this will take off! Especially with the fact that Simon Chin keeps buying up the float so there is less than 5 million in the float now.
heh, then NITE woke up and put 5k@.40. a nice little eow paint nonetheless.
I'm sure there are a lot of big things happening as we speak, just wish we could get some news to get this thing moving
3 news articles posted yesterday. http://www.iris-biotech.de/news/. they are all highly technical like the last round dated on 12/02/2016. too bad there isn't any volume like last time.
And until we get news this is about where it will stay! News will send this soaring however.
That's the one thing I'm not overly happy about is the lack of updates from the company!
down to .32x.35 (CANT x NITE)
NITE now leading on both sides, .30 x .40. maybe some volume will finally return.
another little uptick on the bid. CANT now leading with 10k@.26.
spread coming in a little, with the bid coming up...
That's a fricken big gap, again if and when we get something newsworthy this will go big. Float is so tiny it's not going to take much. Glta
.63?? whacky gap, but still...
I agree and it keeps inching up. I think a little patience is due with this one but it will take off and when it does it goes quick! Look what it was doing about a month ago so with any product rollout news and with less than 3.5 million shares in the float it will spike even quicker!
might be a little wishful thinking, but it sorta looks like the bid has been slowly solidifying over the past week or so.
Seems to me if he is accepting the shares for his salary then he must think that they will really be worth something in the future!
When news about product rollout hits in the new year how fast do you think the price will soar on this unknown gem?
Well with 15 million shares outstanding and the Ceo, Chin Simon owning roughly 11.5 million shares make this roughly a 3.5 million share float!
Well I'm thinking we desperately need news or some kind of update soon! Pretty discouraging
I think so because with such a low float any news will rocket this
out at .45 last week and back in at .15 after talking to Simon Chin. Sounds like more PR's will be released soon and other up coming events will take place soon. Worth while to hold for a few months.
Well regardless of how much money that is its a positive sign for a ceo to continue to buy his company shares.
He wouldn't be buying if he didn't feel the company had promise!
Another form 4 filed yesterday.. Simon Chin purchased another 20k shares @ .19 and .2295.
Positive exit. Reload under 10 cents.
Welcome aboard!
Followers
|
5
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
217
|
Created
|
09/13/08
|
Type
|
Free
|
Moderators |
http://www.irisbiotech.com/index.html << Company Website <<
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |